↓ Skip to main content

Dove Medical Press

The expression of the PI3K/AKT/mTOR pathway in gastric cancer and its role in gastric cancer prognosis

Overview of attention for article published in OncoTargets and therapy, September 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

twitter
3 X users
facebook
1 Facebook page

Citations

dimensions_citation
52 Dimensions

Readers on

mendeley
25 Mendeley
Title
The expression of the PI3K/AKT/mTOR pathway in gastric cancer and its role in gastric cancer prognosis
Published in
OncoTargets and therapy, September 2015
DOI 10.2147/ott.s88592
Pubmed ID
Authors

Jieer Ying, Qi Xu, Bixia Liu, Gu Zhang, Lei Chen, Hongming Pan

Abstract

To analyze the correlation between sequential aspects of the phosphoinositide-3 kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway by immunohistochemistry in the primary lesion of gastric cancer, clinicopathologic factors, and survival in Chinese patients to explore the role of sequential analysis of multiple targets in prognoses. Immunohistochemistry was performed to examine the expression of PI3K, phosphorylated-AKT (p-AKT), and phosphorylated-mTOR (p-mTOR) in 59 primary lesion samples ranging from Stages I to IV after gastrectomy. The correlation between sequential expression of multiple targets, and clinicopathologic factors and survival was analyzed. The positive expression rates of PI3K, p-AKT, and p-mTOR were 49%, 58%, and 56%, respectively. There were eleven cases with three biomarkers positive (19%), 22 cases with two biomarkers positive (37%), and 19 cases with only one biomarker positive (32%). Seven cases (12%) were all negative. Multi-factorial Cox regression analysis showed that neural invasion, vascular invasion, size of the tumor, lymph nodes affected, metastasis, carbohydrate antigen 19-9 level, and PI3K/p-AKT/p-mTOR simultaneous expression were independent prognostic parameters. The risk of death for the cases with two biomarkers positive was 0.367 times that for the cases with three biomarkers positive (P=0.166). The risk of death for the cases with only one biomarker positive was 0.105 times that for the cases with three biomarkers positive (P=0.058). The risk of death for the cases with three biomarkers negative was 0.017 times that for the cases with three biomarkers positive (P=0.022). Our study generated the hypothesis that patients with gastric cancer with simultaneous expression of PI3K/p-AKT/p-mTOR had worse outcome. But we need more rigorous validation in a larger data set.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Austria 1 4%
Unknown 24 96%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 9 36%
Student > Master 5 20%
Researcher 2 8%
Student > Bachelor 2 8%
Lecturer > Senior Lecturer 1 4%
Other 2 8%
Unknown 4 16%
Readers by discipline Count As %
Medicine and Dentistry 5 20%
Agricultural and Biological Sciences 5 20%
Immunology and Microbiology 3 12%
Biochemistry, Genetics and Molecular Biology 2 8%
Chemistry 2 8%
Other 4 16%
Unknown 4 16%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 September 2015.
All research outputs
#16,046,765
of 25,371,288 outputs
Outputs from OncoTargets and therapy
#887
of 3,016 outputs
Outputs of similar age
#147,247
of 276,785 outputs
Outputs of similar age from OncoTargets and therapy
#25
of 100 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 276,785 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 100 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.